Merck (NYSE:MRK) has invested $30 million for nearly a 10% stake in Eikon Therapeutics as Eikon moves toward an IPO. The company has also entered a multi year global oncology collaboration with ...
Guardant Health recently announced a multi-year collaboration with Merck to use its Guardant Infinity Smart liquid and tissue ...
Shield’s FDA-approved blood test drives cancer screening growth, pricing power, and cash-flow upside. Click for this GH ...
Guardant Health is rated a strong buy, driven by its Shield blood-based colorectal cancer screening and a transformative collaboration with Quest Diagnostics. GH’s Shield test addresses major barriers ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted ...
15 abstracts spanning advancements in early detection of recurrence, tumor profiling, and therapy response monitoring Presentations highlight the power of Guardant Health’s blood-based assays to ...
Collaboration enables insights from ConcertAI national database of 5.5M clinical records and Guardant profiling data across 60+ tumor types Longitudinal DNA methylation measurements and comprehensive ...
The first readout from Guardant’s research collaboration with the Parker Institute for Cancer Immunotherapy (PICI) shows Guardant Reveal detected responses to immunotherapy across multiple tumor types ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results